User: Guest

  



DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

8517

Interactions with Platform & by Email *

INTERACTIONS

1192

Unique # Participated *

PARTICIPANTS

256

Responses Validated *

VALIDATIONS

48

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Acute Coronary Syndrome – A Primer.....II-1
Table 1: World Recent Past, Current & Future Analysis for Acute Coronary Syndrome Therapeutics Market - Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....II-1
1$350
   Global ACS Drugs Market Scenario.....II-2 1$100
   Table 2: Leading ACS Drugs with Global Sales Revenues (in US$ billion) for the Year 2008 (includes corresponding Graph/Chart).....II-31$350
   Table 3: Select Leading Myocardial Infarction Drugs Worldwide: Value Sales for 2007 and 2008 in US$ Million (includes corresponding Graph/Chart).....II-41$350
   Table 4: Select Leading Coronary Artery Disease/ Atherosclerosis Drugs Worldwide: Value Sales for 2007 and 2008 in US$ Million (includes corresponding Graph/Chart).....II-5

Table 5: Select Leading Angina Drugs Worldwide: Value Sales for 2007 and 2008 in US$ Million (includes corresponding Graph/Chart).....II-5
1$350
   Table 6: Estimated Number of Products Available for Select ACS Indications (includes corresponding Graph/Chart).....II-6
Key Market Drivers and Constraints.....II-6
Antithrombotics – The Driving Force in Future.....II-6
Combination Products.....II-6
Drug Delivery Technologies.....II-6
1$350
   Fast and Accurate Diagnosis – Reduce Unnecessary Healthcare Costs.....II-7
Patent Expiry of Best Selling Products: A Key Concern for the Industry.....II-7
1$100
   List of Leading Cardiovascular Drugs on the Verse of Patent Expiry.....II-8
Lack of Product Differentiation.....II-8
Fewer Product Introductions.....II-8
Market Characteristics.....II-8
United States and Europe – Far Ahead and Far More Powerful.....II-8
1$100
   Anticoagulants – Remarkable Drug Development Potential.....II-9
Anticoagulants to Lose ACS Indications to Antiplatelets.....II-9
Novel Anticoagulants to Drive Atrial Fibrillation Drug Market.....II-9
1$100
   Protein Therapy Research Promises Cardiovascular Disease Treatment.....II-10
Future Directions: Shape Of Things To Come.....II-10
1$100
   Table 7: Estimated Number of Pipeline Products by Select ACS Indication (includes corresponding Graph/Chart).....II-11

Table 8: Estimated Number of Candidates in Development Phase by Select ACS Indication (includes corresponding Graph/Chart).....II-11
1$350
   List of Cardiovascular (including ACS) Pipeline Products in Phase III Development
  (as of March 2007).....II-12
1$100
   List of Cardiovascular (including ACS) Pipeline Products in Phase II Development
  (as of March 2007).....II-13
1$100
   List of Cardiovascular (including ACS) Pipeline Products in Phase I Development
  (as of March 2007).....II-14
1$100
   List of Cardiovascular (including ACS) Pipeline Products in Pre-clinical Development
  (as of March 2007).....II-15
1$100
   Pharmaceutical Industry: A Review of the Current Scenario.....II-16
Industry Framework.....II-16
Consolidation Gets Underway.....II-16
1$100
   Patent Expiries Giving Way to Generic Drugs.....II-17
Developing Countries Hold the Key to Future Growth.....II-17
Table 9: World Pharmaceutical Industry (2007): BRIC Nations (Brazil, Russia, India and China), & United States Ranked by Percentage Growth (includes corresponding Graph/Chart).....II-17
Impact of the Recession: An Unequivocal Review.....II-17
2$350
   Definition And Pathophysiology.....II-19
Cardiac Circulation and Conduction.....II-19
Acute Coronary Syndrome – A Definition.....II-19
Underlying Cause of ACS.....II-19
Unstable Angina.....II-19
1$100
   Causes and Symptoms.....II-20
Treatment Options.....II-20
Myocardial Infarction (MI).....II-20
1$100
   Non-ST-Segment Elevated Myocardial Infarction (NSTEMI).....II-21
ST-Segment Elevated Myocardial Infarction (STEMI).....II-21
Chain Reaction After an Event of MI.....II-21
Action Plan after an Event of MI.....II-21
Causes and Symptoms.....II-21
1$100
   Drug Treatment Options.....II-22
Epidemiology.....II-22
Cardiovascular Diseases.....II-22
1$100
   Table 10: Region-Wise Incidence and Prevalence of Cardiovascular Diseases in 2006 (includes corresponding Graph/Chart).....II-23
Factors Responsible for Coronary Diseases.....II-23
1$350
   Uncontrollable Risk Factors.....II-24
Ageing Global Population.....II-24
Table 11: World Demographic Trends: People Over 65 as a Percentage of Total Population by Geographic Region- US, Canada, Japan, Europe, Asia-Pacific, and Latin America for years 2000, 2008, 2010, and 2020 (includes corresponding Graph/Chart).....II-24
1$350
   Heredity.....II-25
Gender.....II-25
Diabetes.....II-25
Controllable Risk Factors.....II-25
High Blood Cholesterol.....II-25
HDL Cholesterol.....II-25
1$100
   HDL Cholesterol Levels and Potential Risk of Cardiovascular Disease.....II-26
LDL Cholesterol.....II-26
LDL Cholesterol Levels and Potential Risk of Cardiovascular Disease.....II-26
Triglyceride Levels.....II-26
Triglyceride Level and Potential Risk of Cardiovascular Disease.....II-26
1$100
   Smoking.....II-27
Changing Habits and Lifestyle.....II-27
High Blood Pressure.....II-27
Causative Risk Factors.....II-27
Stress and Anger.....II-27
Obesity.....II-27
1$100
   Disease Investigation And Diagnosis.....II-28
ECG.....II-28
Exercise ECG (ECG Stress Testing).....II-28
1$100
   Test Procedure and Precautions.....II-29
Blood Tests (for the Presence of Cardiac Biomarkers).....II-29
1$100
   Myocardial Infarction Cardiac Biomarkers - Benefits and Limitations.....II-30
C-Reactive Protein.....II-30
1$100
   Necessity of a Cardiac Marker Assay Test.....II-31
How it Works?.....II-31
Need for Early Detection Markers.....II-31
1$100
   Strong Demand for Risk Assessment Markers.....II-32
Invasive Imaging Tests.....II-32
Coronary Angiography (or Cardiac Angiography).....II-32
Test Procedure and Results.....II-32
1$100
   Intravascular Ultrasound (IVUS).....II-33
Test Procedure and Results.....II-33
1$100
   Medication Strategies.....II-34
Anti-ischemic Agents.....II-34
Nitrates.....II-34
1$100
   Description on Some of the Nitrate Drugs for Acute Coronary Syndrome.....II-35
Usage of Nitrates in ACS Indications.....II-35
Unstable Angina (UA).....II-35
Acute Myocardial Infarction (AMI).....II-35
1$100
   ? Blockers.....II-36
List of Indications for Select Beta-blocker Drugs.....II-36
Calcium Channel Blockers.....II-36
1$100
   List of Indications for Select Calcium Channel Blockers.....II-37
ACE and ACE II Inhibitor Drugs.....II-37
Angiotensin Converting Enzyme (ACE) Inhibitors.....II-37
1$100
   List of Different Types of ACE Inhibitors and Products.....II-38
Angiotensin II Receptor Antagonists (ACE II or sartans).....II-38
1$100
   List of Different Types of Angiotensin II Receptor Antagonists and Products.....II-39
Cholesterol Reducing Drugs.....II-39
Statins Lead the Way.....II-39
1$100
   Emerging Leaders.....II-40
Table 12: Leading Cholesterol Reducing Drugs Worldwide: Sales for the years 2004 through 2008 for Lipitor, Crestor and Vytorin (in US$ Billion) (includes corresponding Graph/Chart).....II-40
1$350
   Lack of Product Differentiation Mars Prospects.....II-41
Zocor – The First Statin to Switch to OTC.....II-41
Patent Expiries of Leading Cholesterol Reducers: 2009 and Beyond.....II-41
Anticoagulants.....II-41
Anticoagulant Drug Classes.....II-41
Oral Anticoagulants.....II-41
1$100
   Warfarin.....II-42
Coumadin.....II-42
Injectable Anticoagulants.....II-42
1$100
   Heparin.....II-43
Unfractionated Heparin.....II-43
1$100
   Low Molecular Weight Heparin (LMWH).....II-44
A Snapshot of Available Anticoagulant Therapies.....II-44
1$100
   Antiplatelet Agents.....II-45
List of Indications for Select Antiplatelet Drugs.....II-45
Thrombolytics.....II-45
1$100
   Key Indications Relating to ACS.....II-46
Others.....II-46
Aspirin.....II-46
Oxygen Supply.....II-46
1$100
   Pain Reliving Agents.....II-47
Revascularization Procedures.....II-47
Invasive Treatments.....II-47
Bypass Surgery.....II-47
Percutaneous Transluminal Coronary Angioplasty (Balloon Angioplasty).....II-47
1$100
   Coronary Stents.....II-48
Drug Eluting Stents Steal the Show.....II-48
Applications of Coronary Stents.....II-48
1$100
   Key Stents Delivery Platforms by Select Company.....II-491$100
   Coronary Stents – Leading Players.....II-50
Table 13: Leading Players in the Global Coronary Stents Market (2006-2008) - Percentage Breakdown by Revenues for Boston Scientific, Johnson & Johnson, Abbott, Medtronic, and Others (includes corresponding Graph/Chart).....II-50
1$350
   Bare Metal Stents – Leading Players.....II-51
Table 14: Leading Players in the Global Bare Metal Stents Market (2006-2008) - Percentage Breakdown by Revenues for Abbott, Johnson & Johnson, Boston Scientific, Medtronic, and Others (includes corresponding Graph/Chart).....II-51
1$350
   Drug-Eluting Stents – Leading Players.....II-52
Table 15: Leading Players in the Global Drug-Eluting Stents Market (2006-2008) - Percentage Breakdown by Revenues for Boston Scientific, Johnson & Johnson, Abbott, and Medtronic (includes corresponding Graph/Chart).....II-52
Cell Transplantation – An Emerging Procedure For Chronic Heart Ailments.....II-52
1$350
   The United States.....II-53
Cardiovascular Diseases in the US: A Review.....II-53
Table 16: The US Disease Statistics for Coronary Heart Disease (CHD) & Myocardial Infarction (MI) (includes corresponding Graph/Chart).....II-53
1$350
   AHA Statistics for Coronary Heart Disease.....II-54
Table 17: The US Prevalence of Coronary Heart Disease (CHD) as a Percentage of Total Population by Age group and Sex, in 2005-06 (includes corresponding Graph/Chart).....II-54
1$350
   Table 18: The US Prevalence of Stroke as a Percentage of Total Population by Age group and Sex, in 2005-06 (includes corresponding Graph/Chart).....II-55
Statistics from NCHS and NHLBI on ‘Death Due to Cardiovascular Diseases’.....II-55
1$350
   Table 19: Mortality Rate in the US for the Year 2006 by Cardiovascular Diseases -Percentage Breakdown of Deaths from Coronary Heart Disease, Stroke, High Blood Pressure, Heart Failure, Diseases of the Arteries, and Others (includes corresponding Graph/Chart).....II-56

Table 20: Mortality Rate in the US Males for the Year 2005 by Ailment - Heart Diseases, Cancer, Accidents, Chronic Lower Respiratory Diseases, and Diabetes (includes corresponding Graph/Chart).....II-56
1$350
   Table 21: Mortality Rate in the US Females for the Year 2005 by Ailment - Heart Diseases, Cancer, Chronic Lower Respiratory Diseases, Alzheimer’s, and Accidents (includes corresponding Graph/Chart).....II-57
Fall in Number of Deaths due to Heart Diseases & Strokes.....II-57
1$350
   Senior Citizens at High Risk for Heart Failure.....II-58
Baby Boomers Boost Coronary Stent Market.....II-58
Generics Trigger Price war.....II-58
1$100
   Table 22: US Cardiovascular Drugs Market - Total Prescriptions by Drug Class (in Thousands) for the Years 2008 and 2009 (includes corresponding Graph/Chart).....II-591$350
   Table 23: Select Leading Myocardial Infarction Drugs in the US: Value Sales in US$ Million for the Years 2007 and 2008 (includes corresponding Graph/Chart).....II-60

Table 24: Select Leading Coronary Artery Disease/ Atherosclerosis Drugs in the US: Value Sales in US$ Million for the Years 2007 and 2008 (includes corresponding Graph/Chart).....II-60
1$350
   Table 25: Select Leading Angina Drugs in the US: Value Sales in US$ Million for the Years 2007 and 2008 (includes corresponding Graph/Chart).....II-61
Antihyperlipidemics.....II-61
1$350
   Table 26: US Cardiovascular Drugs Market for Statins (HMG CoA-Reductase Inhibitors) - Type of Statin Ranked by Value Sales in US$ Million for the Year 2007 (includes corresponding Graph/Chart).....II-62

Table 27: US Antihyperlipidemic Drugs Market (2007): Percentage Share Breakdown of Total Prescriptions by Leading Drugs (includes corresponding Graph/Chart).....II-62
1$350
   Anticoagulants and Antiplatelets.....II-63
Table 28: US Anticoagulant Drugs Market (2007): Percentage Share Breakdown of Total Prescriptions by Leading Product (includes corresponding Graph/Chart).....II-63
Drug Development Pipeline.....II-63
1$350
   US Pharmaceutical Sector Scenario.....II-64
Table 29: US Pharmaceutical Market (2008) - Leading Pharmaceutical Companies Ranked by Value Sales in US$ Million (includes corresponding Graph/Chart).....II-64
1$350
   Table 30: US Pharmaceutical Market (2007) - Leading Pharmaceutical Products Ranked by Value Sales in US$ Million (includes corresponding Graph/Chart).....II-651$350
   Table 31: US Pharmaceuticals Market (2008) - Leading Therapeutic Class Ranked by Value Sales in US$ Million (includes corresponding Graph/Chart).....II-661$350
   Table 32: US Cardiovascular Drugs Market (2008) - Leading Companies Ranked by Cardiovascular Drug Sales in US$ Million (includes corresponding Graph/Chart).....II-67
Canada.....II-67
Leading Drugs in Canada.....II-67
1$350
   Table 33: Leading Prescription Drugs in Canada (2006 & 2007) - Number of Dispensed Prescriptions in Million Scripts for Lipitor, Synthroid, Norvasc, Asaphen, Pantoloc, Crestor, Altace, Ratio- Salbutamol Hfa (includes corresponding Graph/Chart).....II-68
Europe.....II-68
European Cardiovascular Diseases Fact Sheet.....II-68
1$350
   Cardiovascular Disease – Risk Factor Profile.....II-69
The Cardiovascular Disease Cost Burden.....II-69
1$100
   Mortality by Heart Attack Declines.....II-70
EU to Face Health Care Expenditure Challenge Head-on.....II-70
1$100
   FDA Approves Prasugrel.....II-71
Efient® (Prasugrel) Obtains Approval by European Commission.....II-71
1$100
   The Medicines Company Obtains Approval for Angiox® by European Union.....II-72
CV Therapeutics Obtains FDA Approval for New Indication for Ranexa.....II-72
1$100
   BMS and Pfizer Announce APPRAISE-1 Results for Apixaban.....II-73
Scottish Medicines Consortium Issues Approval for Various Drugs.....II-73
Schweizerhall Holding AG/Cimex AG to Launch Plavix® (Clopidogrel) Generic.....II-73
Response Bags FDA Clearance for RAMP® NT-proBNP Test.....II-73
PLAVIX® Receives FDA Nod.....II-73
1$100
   Sanofi-aventis Wins FDA Approval to Use Lovenox in STEMI Patients.....II-74
GlaxoSmithKline Receives FDA Approval for Arixtra Injection.....II-74
GlaxoSmithKline Wins EMEA Approval for Arixtra.....II-74
GlaxoSmithKline Wins MHLW Approval for Arixtra.....II-74
1$100
   Ranbaxy Introduces Pravastatin Sodium 80mg Tablets in the US.....II-75
GlaxoSmithKline Introduces Coreg CR™.....II-75
1$100
   Pfizer Acquires Wyeth.....II-76
Sanofi-aventis Mexico Takes Over Laboratorios Kendrick.....II-76
Arca biopharma Merges with Nuvelo.....II-76
1$100
   Merck Merges Business with Schering-Plough.....II-77
Portola Pharmaceuticals Enters into Partnership with Novartis.....II-77
Richter-Helm Signs Agreement with Athera Biotechnologies.....II-77
Daiichi Sankyo Sets Up Subsidiary.....II-77
1$100
   Zydus Cadila Joins Forces with Eli Lilly for Cardiovascular Drug Research.....II-78
AtCor Medical Enters into Contract with Pharmaceutical Company.....II-78
Takeda Acquires Millenium Pharmaceuticals.....II-78
Daiichi- Sankyo Acquires Controlling Stake in Ranbaxy.....II-78
1$100
   GlaxoSmithKline Acquires Bristol Myers Squibb’s Egyptian Business.....II-79
Shionogi Acquires Sciele Pharma.....II-79
GlaxoSmithKline Acquires Reliant Pharmaceuticals.....II-79
1$100
   Recordati Acquires Yeni Ilac.....II-80
China Sky One to Take Over Heilongjiang Tianlong Pharmaceutical.....II-80
King Pharmaceuticals to Acquire Alpharma.....II-80
1$100
   GlaxoSmithKline to Acquire Bristol-Myers Squibb Pakistan.....II-81
Meda Signs Deal to Take Over Roche Pharmaceutical Products.....II-81
Belupo and Farmavita Announce Merger.....II-81
Iroko Acquires Aggrastat’s Rights from Merck.....II-81
Biological E Collaborates with Choncept and Heparinex.....II-81
1$100
   Merck Serono Signs Distribution Agreement with Bristol-Myers Squibb.....II-82
BMS and KAI Sign Pact to Develop, Commercialize Cardiovascular Drug.....II-82
CV Therapeutics and Menarini Group Sign Deal for Ranexa.....II-82
1$100
   Forest Labs and Daiichi Sankyo Terminate Azor Co-Promotion Agreement.....II-83
Daiichi Sankyo Submits Application for Antihypertensive Drug Approval.....II-83
Daiichi Sankyo Establishes Subsidiary in Ireland.....II-83
1$100
   PAION Announces Acquisition of Global Rights to Trigen’s flovagatran.....II-84
Cardiovascular Systems Merges with Replidyne.....II-84
Amic Recieves Non-Exclusive License from Roche Diagnostics.....II-84
Iroko Pharmaceuticals Wins Rights to Aggrastat®.....II-84
1$100
   Sepracor Acquires Oryx Pharmaceuticals.....II-85
GSK Acquires Reliant Pharmaceuticals.....II-85
Schering-Plough Takes Over Organon BioSciences.....II-85
1$100
   Merck Serono and Bristol-Myers Squibb Ink Latin American Distribution Deal.....II-86
Merck Acquires NovaCardia.....II-86
Bristol-Myers and Pfizer Ink Development and Commercialization Agreements.....II-86
1$100
   Inverness Acquires Biosite.....II-87
Siemens Acquires Diagnostic Division of Bayer Healthcare.....II-87
Siemens Announces Acquisition of Dade Behring.....II-87
Inverness Acquires Cholestech.....II-87
1$100
   Sanofi-aventis Acquires Rights for Panaldine from Daiichi Sankyo.....II-88
Corautus Genetics and VIA Pharmaceuticals Sign Merger Agreement.....II-88
Alchemia Inks Marketing Alliance with Dr. Reddy’s for Heparin.....II-88
Recordati- Berlin Chemie Expand Licensing Agreement.....II-88
1$100
   Abbott Laboratories Inc. (US).....II-89
AstraZeneca (UK).....II-89
1$100
   Bayer AG (Germany).....II-90
Boehringer Ingelheim GmbH (Germany).....II-90
Bristol-Myers Squibb Company (US).....II-90
1$100
   Daiichi Sankyo Company Limited (Japan).....II-91
Dr. Reddy's Laboratories Ltd. (India).....II-91
1$100
   Eli Lilly and Company (US).....II-92
F. Hoffmann-La Roche Ltd. (Switzerland).....II-92
1$100
   GlaxoSmithKline plc (UK).....II-93
Inverness Medical Innovations, Inc. (US).....II-93
1$100
   Merck & Co., Inc. (US).....II-94
Medicure Inc. (Canada).....II-94
Novartis AG (Switzerland).....II-94
1$100
   Pfizer, Inc. (US).....II-95
Wyeth (US).....II-95
1$100
   Sanofi-Aventis SA (France).....II-96
Schering-Plough Corp. (US).....II-96
1$100
   Siemens Healthcare Diagnostics, Inc. (US).....II-97
Takeda Pharmaceutical Company Limited (Japan).....II-97
1$100
   The Medicines Company (US).....II-981$100
    
 
 


Sales queries: Sales@StrategyR.com
Research queries: Info411@StrategyR.com